A Phase I, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Palovarotene in Male and Female Participants With Moderate and Severe Hepatic Impairment and Matched Participants With Normal Hepatic Function
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Pharmacokinetics
- Sponsors Ipsen
Most Recent Events
- 02 Mar 2026 Status changed from recruiting to completed.
- 11 Apr 2025 New trial record